undamentalytics Newsletter
Sign in

Coherus Oncology, Inc. cash flow statement

In fiscal 2025, Coherus Oncology, Inc.'s operations generated −$139m of cash; it spent $0 on capital projects, leaving free cash flow of −$139m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−1815−24−108−253−200−15928154−37−241−175−20−139−186
Depreciation and amortisation001233333443212
Stock-based pay0211172733353438515143281711
Capital spending203675127120000
Free cash flow−2015−27−114−259−205−16027147−39−243−175−20−139−186
Free cash flow after stock pay−2013−38−131−286−238−195−7109−90−294−218−48−155−197
Share buybacks——0————————————
Shares issued—————————41——1——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CHRS vs OCULCHRS vs GOSSCHRS vs SIGA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Coherus Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Coherus Oncology, Inc.